Atlas Trials

Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Clinical trial NCT06385548 · WITHDRAWN

Trial details

NCT number
NCT06385548
Sponsor
Vall d'Hebron Institute of Oncology
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Endometrial Cancer
Start date
2024-05-01
Primary completion
2024-05-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.